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Introduction {#jdi12957-sec-0005}
============

Latent autoimmune diabetes in adults (LADA) refers to adult diabetes patients who are initially non‐insulin requiring, but have type 1 diabetes mellitus‐associated autoantibodies and who often progress to insulin dependency. LADA manifests as a wide spectrum of heterogeneous clinical and metabolic phenotypes that are midway between those of classic type 1 diabetes mellitus and type 2 diabetes mellitus. It is estimated that LADA accounts for 4--14% of patients with a diagnosis of type 2 diabetes mellitus, making it more common than classic childhood‐onset type 1 diabetes mellitus in some ethnic groups[1](#jdi12957-bib-0001){ref-type="ref"}.

During recent years, glycemic variability (GV) has gained much research interest as a contributor, beyond glycated hemoglobin A~1c~ (HbA~1c~), to the development of diabetes‐related complications[2](#jdi12957-bib-0002){ref-type="ref"}. Mechanistic and clinical studies suggested that glucose fluctuations might incur oxidative stress and endothelial dysfunction[3](#jdi12957-bib-0003){ref-type="ref"}, [4](#jdi12957-bib-0004){ref-type="ref"}, [5](#jdi12957-bib-0005){ref-type="ref"}, [6](#jdi12957-bib-0006){ref-type="ref"}, which have deleterious effects on both the microvasculature and macrovasculature. Recently, several epidemiology studies investigating the associations of GV and diabetic complications were reported, and the results were inconsistent. Of note, no study examined the effect of GV on the risk of diabetic complications in patients with LADA. Additionally, the relationships between short‐term indices of GV (as measured by continuous glucose monitoring \[CGM\]) and diabetic retinopathy (DR) in individuals with type 2 diabetes mellitus are largely unknown, with only one study reported with a small sample size[7](#jdi12957-bib-0007){ref-type="ref"}.

Therefore, the aim of the present study was to evaluate the link between several short‐term GV measurements, as assessed by CGM, and the prevalence of DR in patients with LADA and type 2 diabetes mellitus.

Methods {#jdi12957-sec-0006}
=======

Study Populations {#jdi12957-sec-0007}
-----------------

In the present study, LADA patients were consecutively enrolled, and type 2 diabetes mellitus patients were randomly selected from the patients admitted to the Department of Endocrinology and Metabolism of Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital, Shanghai, China, between July, 2005, and December, 2015. Diabetes was diagnosed according to the 1999 World Health Organization criteria[8](#jdi12957-bib-0008){ref-type="ref"}. LADA was defined according to the Chinese consensus on LADA as follows: (i) aged ≥18 years at the onset of diabetes; (ii) positivity for autoantibodies to glutamic acid decarboxylase and/or islet antigen 2; and (iii) insulin independence for 6 months after diagnosis. Diabetes patients negative for autoantibodies to glutamic acid decarboxylase and autoantibodies to islet antigen 2 were defined as type 2 diabetes mellitus. All patients were aged 18--75 years and were taking a stable antidiabetic regimen for the previous 3 months. Those with acute complications of diabetes including diabetic ketoacidosis, hyperglycemic hyperosmolar state or severe and recurrent hypoglycemic events during the past 3 months were excluded from the study. The study protocol was approved by the ethics committees of Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital in accordance with the principles of the Helsinki Declaration. Before participation, written informed consent was obtained from each participant.

CGM Parameters {#jdi12957-sec-0008}
--------------

All participants were continuously monitored for 72 h with a retrospective CGM system (Medtronic Inc., Northridge, CA, USA), as previously described[9](#jdi12957-bib-0009){ref-type="ref"}. After the monitoring, GV metrics were calculated with computer software. Measures of intraday GV included the standard deviation (SD) of sensor glucose values, glucose coefficient of variation (CV) and the mean amplitude of glycemic excursions (MAGE). CV was calculated as SD divided by the mean of sensor glucose readings. MAGE was calculated as the arithmetic mean of the differences between consecutive peaks and nadirs. Only excursions of \>1 SD of the mean glycemic values were selected for the calculation of MAGE. All participants adhered to the original therapy regimen during the 72‐h CGM period and followed a standard dietary pattern at the same time.

Anthropometric and Biochemical Measurements {#jdi12957-sec-0009}
-------------------------------------------

All patients underwent anthropometric measurements including height, weight and blood pressure. Body mass index was calculated as weight (kg) divided by the square of height (m). Blood pressure (BP) was measured twice using a standard mercury sphygmomanometer and the average was documented. Venous blood samples were collected after an overnight fast. Biochemical parameters including fasting plasma glucose, HbA~1c~, C‐peptide, triglycerides (TG), total cholesterol, high‐density lipoprotein cholesterol and low‐density lipoprotein cholesterol were assayed, as previously reported[10](#jdi12957-bib-0010){ref-type="ref"}.

Assessment of DR {#jdi12957-sec-0010}
----------------

For each patient, fundus photography was carried out for both eyes with a digital non‐mydriatic camera (Canon CR6‐45NM; Canon, Lake Success, NY, USA) following a standardized protocol. The status of DR was diagnosed by an ophthalmologist blinded to the characteristics of patients according to the International Classification of Diabetic Retinopathy[11](#jdi12957-bib-0011){ref-type="ref"}. When binoculus DRs were graded differently, the advanced one was selected.

Statistical Analysis {#jdi12957-sec-0011}
--------------------

Continuous variables that followed a normal distribution were compared using Student\'s *t*‐test, whereas those with skewed distributions were compared by the Mann--Whitney *U*‐test. The χ^2^‐test was used to determine the differences between groups for categorical variables. In the univariate logistic regression analysis, the associations of potential clinical risk factors, including GV metrics, with DR were evaluated. Those variables with *P*‐values \<0.25, as well as GV metrics, were considered for entry into a multivariate logistic regression model to examine the predictors of DR. The Cochran--Armitage trend test was used to evaluate the increasing prevalence of DR as a function of quartiles of GV metrics. To avoid multicollinearity, separate multivariate logistic regression models were constructed for SD (model 1), CV (model 2) and MAGE (model 3), respectively. The correlations among the GV metrics can be found in Table [S1](#jdi12957-sup-0001){ref-type="supplementary-material"}. Statistical analyses were carried out using SPSS software version 17.0 (SPSS Inc., Chicago, IL, USA). A *P*‐value of \<0.05 (two‐tailed) was considered statistically significant.

Results {#jdi12957-sec-0012}
=======

Clinical characteristics of the patients are shown in Table [1](#jdi12957-tbl-0001){ref-type="table"}. A total of 2,927 type 2 diabetes mellitus and 192 LADA patients were finally included in the analyses. The prevalence of DR was 26.4 and 20.3% in type 2 diabetes mellitus and LADA patients (*P \< *0.001), respectively. By comparison with type 2 diabetes mellitus patients, LADA patients were leaner, had a more favorable blood pressure (including systolic and diastolic BP) and lipid profile (including TG, high‐density lipoprotein cholesterol and low‐density lipoprotein cholesterol), lower fasting C‐peptide and higher GV (including SD, CV and MAGE) during CGM. In addition, patients with LADA were more likely to be treated with insulin and statins, and had lower propensity to receive renin--angiotensin aldosterone system inhibitors than patients with type 2 diabetes mellitus. For type 2 diabetes mellitus patients, the age, duration, systolic BP, TG, HbA~1c~, use of oral antidiabetic agents, insulin and renin--angiotensin aldosterone system inhibitors, and all four GV metrics differed significantly between those with and without DR. For LADA patients, significant differences in sex, duration, systolic and diastolic BP, and the use of calcium‐channel blockers were observed between individuals with and without DR.

###### 

Clinical characteristics of participants

  Parameters                     Type 2 diabetes mellitus   LADA                                                                                                                                          
  ------------------------------ -------------------------- -------------- -------------------------------------------------------- ------------------------------------------------------ -------------- --------------------------------------------------------
  Age (years)                    57.7 ± 10.1                57.3 ± 10.4    58.8 ± 9.1[\*\*](#jdi12957-note-0001){ref-type="fn"}     56.4 ± 10.1                                            56.3 ± 10.2    56.8 ± 9.7
  Sex, male (%)                  42.70                      42.40          43.70                                                    52.1[\*](#jdi12957-note-0001){ref-type="fn"}           54.20          43.6[\*\*](#jdi12957-note-0001){ref-type="fn"}
  Diabetes duration (years)      7.7 ± 6.3                  6.6 ± 5.8      10.8 ± 6.6[\*\*](#jdi12957-note-0001){ref-type="fn"}     7.7 ± 6.4                                              7.0 ± 6.2      10.6 ± 6.2[\*\*](#jdi12957-note-0001){ref-type="fn"}
  BMI (kg/m^2^)                  25.1 ± 3.4                 25.1 ± 3.4     24.9 ± 3.4                                               23.2 ± 5.2[\*](#jdi12957-note-0001){ref-type="fn"}     23.1 ± 5.7     23.2 ± 2.5
  SBP (mmHg)                     131.5 ± 17.2               130.0 ± 16.3   135.6 ± 18.9[\*\*](#jdi12957-note-0001){ref-type="fn"}   127.2 ± 16.6[\*](#jdi12957-note-0001){ref-type="fn"}   125.0 ± 14.4   136.4 ± 21.6[\*\*](#jdi12957-note-0001){ref-type="fn"}
  DBP (mmHg)                     80.4 ± 9.5                 80.2 ± 9.4     81 ± 9.6                                                 77.6 ± 9.1[\*](#jdi12957-note-0001){ref-type="fn"}     76.7 ± 8.6     81.2 ± 10.3[\*\*](#jdi12957-note-0001){ref-type="fn"}
  TC (mmol/L)                    4.8 ± 1.1                  4.7 ± 1.1      4.8 ± 1.2                                                4.6 ± 1.0                                              4.6 ± 1.0      4.9 ± 1.2
  TG (mmol/L)                    2.0 ± 1.8                  2.0 ± 1.9      1.8 ± 1.6[\*\*](#jdi12957-note-0001){ref-type="fn"}      1.2 ± 1.2[\*](#jdi12957-note-0001){ref-type="fn"}      1.2 ± 1.3      1.2 ± 0.8
  HDL‐C (mmol/L)                 1.1 ± 0.3                  1.1 ± 0.3      1.1 ± 0.3                                                1.4 ± 0.4[\*](#jdi12957-note-0001){ref-type="fn"}      1.4 ± 0.4      1.4 ± 0.5
  LDL‐C (mmol/L)                 3.2 ± 1.0                  3.2 ± 1.0      3.2 ± 1.0                                                2.8 ± 0.9[\*](#jdi12957-note-0001){ref-type="fn"}      2.7 ± 0.8      2.9 ± 1.1
  HbA~1c~ (%)                    8.9 ± 2.1                  8.8 ± 2.2      9.2 ± 2.0[\*\*](#jdi12957-note-0001){ref-type="fn"}      9.0 ± 2.0                                              8.9 ± 2.1      9.4 ± 1.9
  Fasting C‐p (ng/mL)            1.9 ± 1.3                  2.1 ± 1.3      1.6 ± 1.0[\*\*](#jdi12957-note-0001){ref-type="fn"}      0.9 ± 1.0[\*](#jdi12957-note-0001){ref-type="fn"}      0.9 ± 1.0      0.8 ± 1.1
  Diabetes treatment (%)                                                                                                                                                                                  
  OAD                            55.3                       58.2           47.9[\*\*](#jdi12957-note-0001){ref-type="fn"}           54.5                                                   55.7           50.0
  Insulin                        68.0                       62.8           81.2[\*\*](#jdi12957-note-0001){ref-type="fn"}           93.0[\*](#jdi12957-note-0001){ref-type="fn"}           92.6           94.7
  Anti‐hypertensive agents (%)                                                                                                                                                                            
  RAAS inhibitors                40.9                       39.4           45.0[\*\*](#jdi12957-note-0001){ref-type="fn"}           26.6[\*](#jdi12957-note-0001){ref-type="fn"}           25.0           33.3
  Calcium‐channel blockers       17.6                       17.1           19.2                                                     12.6                                                   9.5            25.9[\*\*](#jdi12957-note-0001){ref-type="fn"}
  Beta‐blockers                  7.8                        8.1            7.2                                                      7.7                                                    6.9            11.1
  Diuretics                      2.7                        2.3            3.7                                                      2.1                                                    2.6            0.0
  Lipid‐lowering agents (%)                                                                                                                                                                               
  Statins                        24.0                       23.4           25.8                                                     35.0[\*](#jdi12957-note-0001){ref-type="fn"}           35.3           33.3
  Fibrates                       10.8                       11.5           9.0                                                      8.4                                                    10.3           0.0
  GV metrics                                                                                                                                                                                              
  SD (mmol/L)                    2.3 ± 0.9                  2.2 ± 0.9      2.4 ± 0.9[\*\*](#jdi12957-note-0001){ref-type="fn"}      2.8 ± 0.9[\*](#jdi12957-note-0001){ref-type="fn"}      2.8 ± 0.9      2.9 ± 0.9
  CV (%)                         25.5 ± 8.5                 25.2 ± 8.3     26.5 ± 9.0[\*\*](#jdi12957-note-0001){ref-type="fn"}     30.7 ± 9.0[\*](#jdi12957-note-0001){ref-type="fn"}     31.3 ± 9.5     28.9 ± 7.0
  MAGE (mmol/L)                  5.8 ± 2.5                  5.7 ± 2.4      6.1 ± 2.5[\*\*](#jdi12957-note-0001){ref-type="fn"}      7.4 ± 2.7[\*](#jdi12957-note-0001){ref-type="fn"}      7.4 ± 2.8      7.4 ± 2.5

Data are mean ± standard deviation or percentage unless otherwise indicated. \**P *\<* *0.05 for LADA versus type 2 diabetes mellitus; \*\**P *\<* *0.05 for diabetic retinopathy (DR) versus non‐DR in either type 2 diabetes mellitus or latent autoimmune diabetes of the adult (LADA). BMI, body mass index; C‐p, C‐peptide; CV, coefficient of variation; DBP, diastolic blood pressure; GV, glycemic variability; HbA~1c~, glycated hemoglobin A~1c~; HDL‐C, high‐density lipoprotein cholesterol; INS, insulin; LDL‐C, low‐density lipoprotein cholesterol; MAGE, mean amplitude of glycemic excursions; OAD, oral anti‐diabetic agents; RAAS, renin--angiotensin--aldosterone system; SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol; TG, triglyceride.

John Wiley & Sons, Ltd

Univariate logistic regression was carried out to assess the crude relationship of potential risk factors with DR (Table [2](#jdi12957-tbl-0002){ref-type="table"}). For type 2 diabetes mellitus, the age, duration, systolic BP, TG, HbA~1c~ and all metrics of GV were significantly associated with DR (all *P \< *0.05). In LADA, however, only the duration, systolic BP and diastolic BP were identified as significant risk factors for DR (all *P \< *0.05), whereas the relationship between GV metrics and DR did not reach statistical significance (all *P *≥* *0.177).

###### 

Associations of potential risk factors with diabetic retinopathy in type 2 diabetes mellitus and latent autoimmune diabetes of the adult analyzed by univariate logistic regression

  Variables                                            Type 2 diabetes mellitus   LADA                          
  ---------------------------------------------------- -------------------------- --------- ------------------- -------
  Age                                                  1.02 (1.01--1.02)          \<0.001   1.00 (0.97--1.04)   0.782
  Sex                                                  1.06 (0.90--1.25)          0.480     0.65 (0.32--1.32)   0.236
  Duration                                             1.11 (1.10--1.13)          \<0.001   1.09 (1.03--1.15)   0.002
  BMI                                                  0.98 (0.95--1.00)          0.092     1.00 (0.93--1.08)   0.926
  SBP                                                  1.02 (1.01--1.02)          \<0.001   1.04 (1.02--1.06)   0.001
  DBP                                                  1.01 (1.00--1.02)          0.072     1.06 (1.01--1.10)   0.012
  TC                                                   1.03 (0.96--1.11)          0.400     1.31 (0.93--1.85)   0.125
  TG                                                   0.93 (0.88--0.98)          0.011     0.99 (0.74--1.33)   0.964
  HDL‐C                                                1.29 (0.99--1.67)          0.055     1.66 (0.72--3.80)   0.232
  LDL‐C                                                1.02 (0.94--1.11)          0.657     1.14 (0.77--1.69)   0.500
  HbA~1c~                                              1.08 (1.04--1.13)          \<0.001   1.13 (0.95--1.34)   0.158
  SD[\[Link\]](#jdi12957-note-0002){ref-type="fn"}     1.30 (1.19--1.41)          \<0.001   1.05 (0.72--1.53)   0.788
  CV[\[Link\]](#jdi12957-note-0002){ref-type="fn"}     1.16 (1.07--1.26)          \<0.001   0.75 (0.49--1.14)   0.177
  MAGE[\[Link\]](#jdi12957-note-0002){ref-type="fn"}   1.21 (1.11--1.31)          \<0.001   0.97 (0.66--1.44)   0.888

Odds ratios and *P*‐values were calculated for each one standard deviation (SD) increase in SD, coefficient of variation (CV) or mean amplitude of glycemic excursions (MAGE). BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; DR, diabetic retinopathy; HbA~1c~, glycated hemoglobin A~1c~; HDL‐C, high‐density lipoprotein cholesterol; LADA, latent autoimmune diabetes of the adult; LDL‐C, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride.

John Wiley & Sons, Ltd

Patients were subsequently stratified according to the quartiles of SD, CV and MAGE in LADA and type 2 diabetes mellitus, respectively. As shown in Figure [1](#jdi12957-fig-0001){ref-type="fig"}, the prevalence of DR increased with ascending quartiles of SD and MAGE in type 2 diabetes mellitus (all *P* for trend ≤0.001), but not in LADA (all *P* for trend \>0.05).

![The prevalence of diabetic retinopathy (DR) according to quartiles of glycemic variability metrics in latent autoimmune diabetes of the adult (LADA) and type 2 diabetes mellitus (T2DM). (a) The cut‐off values for standard deviation (SD) quartiles were 1.6, 2.2 and 2.8 mmol/L in type 2 diabetes mellitus patients, and 2.2, 2.7 and 3.3 mmol/L in LADA patients. (b) The cut‐off values for coefficient of variation (CV) quartiles were 19.5, 24.6 and 31.1% in type 2 diabetes mellitus and 23.4, 30.4 and 36.3% in LADA. (c) The cut‐off values for mean amplitude of glycemic excursions (MAGE) quartiles were 4.0, 5.5 and 7.3 mmol/L in type 2 diabetes mellitus and 5.3, 6.8 and 9.2 mmol/L in LADA.](JDI-10-753-g001){#jdi12957-fig-0001}

Based on the results of the univariate analyses, variables with *P*‐values \<0.25 were included in the multivariate logistic regression model (Table [3](#jdi12957-tbl-0003){ref-type="table"},[4](#jdi12957-tbl-0004){ref-type="table"}). We found that SD was independently associated with DR (OR 1.15, *P = *0.017) in type 2 diabetes mellitus after adjusting for age, duration, body mass index, systolic BP, diastolic BP, TG, high‐density lipoprotein cholesterol and HbA~1c~. However, the relationships of CV and MAGE with DR (*P = *0.194 and *P = *0.251, respectively) were not significant. For LADA, no metrics of GV were identified as independent risk factors of DR (SD: *P = *0.175; CV: *P = *0.769; MAGE: *P = *0.388) after adjustment of covariates.

###### 

Independent associations of potential risk factors with diabetic retinopathy in type 2 diabetes mellitus

  Variables                                      Model 1             Model 2   Model 3                                           
  ---------------------------------------------- ------------------- --------- ------------------- --------- ------------------- ---------
  Age                                            0.98 (0.97--0.99)   0.001     0.98 (0.97--0.99)   0.001     0.98 (0.97--0.99)   0.001
  Duration                                       1.11 (1.09--1.13)   \<0.001   1.12 (1.10--1.14)   \<0.001   1.12 (1.10--1.14)   \<0.001
  BMI                                            0.99 (0.96--1.02)   0.584     0.99 (0.96--1.02)   0.516     0.99 (0.96--1.02)   0.552
  SBP                                            1.02 (1.01--1.03)   \<0.001   1.02 (1.01--1.03)   \<0.001   1.02 (1.01--1.03)   \<0.001
  DBP                                            1.00 (0.98--1.01)   0.492     1.00 (0.98--1.01)   0.495     1.01 (0.98--1.01)   0.476
  TG                                             0.93 (0.87--0.99)   0.030     0.93 (0.87--0.99)   0.031     0.93 (0.87--0.99)   0.027
  HDL‐C                                          0.91 (0.65--1.27)   0.574     0.91 (0.65--1.28)   0.594     0.92 (0.66--1.30)   0.640
  HbA~1c~                                        1.08 (1.02--1.14)   0.004     1.10 (1.05--1.16)   \<0.001   1.10 (1.04--1.15)   \<0.001
  SD[\*](#jdi12957-note-0005){ref-type="fn"}     1.15 (1.03--1.29)   0.017     /                   /         /                   /
  CV[\*](#jdi12957-note-0005){ref-type="fn"}     /                   /         1.07 (0.97--1.19)   0.194     /                   /
  MAGE[\*](#jdi12957-note-0005){ref-type="fn"}   /                   /         /                   /         1.07 (0.96--1.19)   0.251

Model 1 is adjusted for age, duration, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), triglyceride (TG), high‐density lipoprotein cholesterol (HDL‐C), glycated hemoglobin A~1c~ (HbA~1c~) and standard deviation (SD); model 2 is adjusted for age, duration, BMI, SBP, DBP, TG, HDL‐C, HbA~1c~ and coefficient of variation (CV); model 3 is adjusted for age, duration, BMI, SBP, DBP, TG, HDL‐C, HbA~1c~ and mean amplitude of glycemic excursions (MAGE). \*Odds ratios and *P*‐values were calculated for each one standard deviation increase in SD, CV or MAGE. CI, confidence interval.

John Wiley & Sons, Ltd

###### 

Independent associations of potential risk factors with diabetic retinopathy in latent autoimmune diabetes of the adult

  Variables                                      Model 1             Model 2   Model 3                                         
  ---------------------------------------------- ------------------- --------- ------------------- ------- ------------------- -------
  Sex                                            0.26 (0.08--0.82)   0.021     0.24 (0.08--0.75)   0.014   0.26 (0.08--0.84)   0.023
  Duration                                       1.10 (1.01--1.20)   0.034     1.11 (1.02--1.22)   0.018   1.10 (1.01--1.20)   0.036
  BMI                                            0.98 (0.80--1.19)   0.827     0.98 (0.81--1.20)   0.860   0.99 (0.81--1.21)   0.922
  SBP                                            1.03 (0.99--1.07)   0.152     1.03 (0.99--1.07)   0.221   1.03 (0.99--1.07)   0.199
  DBP                                            1.01 (0.93--1.10)   0.789     1.01 (0.93--1.10)   0.762   1.01 (0.93--1.10)   0.811
  TC                                             1.06 (0.60--1.88)   0.828     1.11 (0.63--1.94)   0.729   1.08 (0.62--1.90)   0.780
  HDL‐C                                          0.55 (0.14--2.23)   0.405     0.73 (0.19--2.85)   0.654   0.62 (0.15--2.51)   0.506
  HbA~1c~                                        1.30 (0.98--1.73)   0.070     1.34 (1.02--1.76)   0.038   1.30 (0.98--1.73)   0.071
  SD[\*](#jdi12957-note-0005){ref-type="fn"}     1.43 (0.85--2.39)   0.175     /                   /       /                   /
  CV[\*](#jdi12957-note-0005){ref-type="fn"}     /                   /         0.92 (0.54--1.59)   0.769   /                   /
  MAGE[\*](#jdi12957-note-0005){ref-type="fn"}   /                   /         /                   /       1.27 (0.74--2.21)   0.388

Model 1 is adjusted for age, duration, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), high‐density lipoprotein cholesterol (HDL‐C), glycated hemoglobin A~1c~ (HbA~1c~) and standard deviation (SD); model 2 is adjusted for age, duration, BMI, SBP, DBP, TC, HDL, HbA~1c~ and coefficient of variation (CV); model 3 is adjusted for age, duration, BMI, SBP, DBP, TC, HDL, HbA~1c~ and MAGE. \*ORs and *P*‐values were calculated for each one standard deviation increase in SD, CV or mean amplitude of glycemic excursions (MAGE). CI, confidence interval.

John Wiley & Sons, Ltd

Discussion {#jdi12957-sec-0013}
==========

There is emerging evidence that GV is a contributor to the development of diabetes‐related complications. For example, an *in vitro* study showed that intermittent high glucose increased nitrotyrosine, 8‐hydroxydeoxyguanosine (two markers of oxidative stress) and apoptosis levels in human umbilical vein endothelial cells compared with a stable high glucose condition[6](#jdi12957-bib-0006){ref-type="ref"}. *In vivo*, Horvath *et al*.[4](#jdi12957-bib-0004){ref-type="ref"} reported that exaggerated alterations in blood glucose ("glycemic swings") stimulated nitrotyrosine production and endothelial dysfunction in streptozotocin‐induced diabetic rats. Furthermore, the extent of endothelial dysfunction in rats with "glycemic swings" was even more pronounced than in untreated diabetic rats. Using the hyperglycemic clamp, Ceriello *et al*.[3](#jdi12957-bib-0003){ref-type="ref"} found that oscillating glucose between 5 and 15 mmol/L every 6 h for 24 h led to further deterioration of endothelial dysfunction and oxidative stress compared with constant high glucose (10 or 15 mmol/L) in both healthy individuals and patients with type 2 diabetes.

To date, numerous epidemiology studies examined the relationship between GV and diabetic complications in type 1 diabetes mellitus and type 2 diabetes mellitus patients, and the results were conflicting[12](#jdi12957-bib-0012){ref-type="ref"}, [13](#jdi12957-bib-0013){ref-type="ref"}, [14](#jdi12957-bib-0014){ref-type="ref"}, [15](#jdi12957-bib-0015){ref-type="ref"}, [16](#jdi12957-bib-0016){ref-type="ref"}, [17](#jdi12957-bib-0017){ref-type="ref"}. Of note, the broad concept of GV generally includes both long‐term and short‐term GV. The latter refers to intraday or interday GV, and is often measured by self‐monitoring of blood glucose or CGM. Currently, information on the association between short‐term GV and DR is limited[7](#jdi12957-bib-0007){ref-type="ref"}, [13](#jdi12957-bib-0013){ref-type="ref"}, [14](#jdi12957-bib-0014){ref-type="ref"}, [15](#jdi12957-bib-0015){ref-type="ref"}, [18](#jdi12957-bib-0018){ref-type="ref"}, [19](#jdi12957-bib-0019){ref-type="ref"}. In type 1 diabetes mellitus, four studies using data from self‐monitoring of blood glucose reported negative findings[13](#jdi12957-bib-0013){ref-type="ref"}, [14](#jdi12957-bib-0014){ref-type="ref"}, [15](#jdi12957-bib-0015){ref-type="ref"}, [18](#jdi12957-bib-0018){ref-type="ref"}, and one small study using CGM data observed a positive result[19](#jdi12957-bib-0019){ref-type="ref"}. However, there is only one study that investigated the relationship between short‐term GV and DR in patients with type 2 diabetes mellitus[7](#jdi12957-bib-0007){ref-type="ref"}. In that study, 33 patients with type 2 diabetes mellitus and 35 with type 1 diabetes mellitus were enrolled and underwent CGM for 72 h. The authors reported that two parameters of GV (SD and continuous overlapping net glycemic action calculated every 2 h) showed a bivariate association with DR, although the significance did not remain in the multivariate analysis. Furthermore, their study was hampered by the small sample size. Additionally, patients with type 1 diabetes mellitus or type 2 diabetes mellitus were combined in the analysis to increase statistical power, thereby resulting in the heterogeneity of participants. In the present study comprising 2,927 type 2 diabetes mellitus patients, we found SD, as assessed by CGM, was significantly associated with DR after adjusting for confounders, indicating that GV might modify the risk of DR independent of HbA~1c~.

To the best of our knowledge, this is the first study to examine the link between GV and diabetes‐related complications in patients with LADA. Consistent with previous studies[20](#jdi12957-bib-0020){ref-type="ref"}, [21](#jdi12957-bib-0021){ref-type="ref"}, [22](#jdi12957-bib-0022){ref-type="ref"}, we found that patients with LADA had fewer cardiometabolic risk factors, as evidenced by lower body mass index, lower blood pressure and better lipid profiles compared with individuals with type 2 diabetes mellitus. In addition, the prevalence of DR in LADA was significantly lower than in type 2 diabetes mellitus (20.3 vs 26.4%, *P \< *0.001). This finding, in light of the fact that patients with LADA had significantly higher levels of all GV metrics than patients with type 2 diabetes mellitus, suggests different roles of GV in type 2 diabetes mellitus and LADA in the development of DR. Indeed, the GV metrics did not relate to prevalent DR in either the univariate or multivariate logistic regression analysis in LADA. A possible explanation for the non‐significant relationship between GV and DR could be the intrinsic heterogeneity of LADA. Different titers and combinations of autoantibodies were shown to discriminate clinically distinct groups of LADA[20](#jdi12957-bib-0020){ref-type="ref"}, [23](#jdi12957-bib-0023){ref-type="ref"}. For example, LADA patients with higher titers of autoantibodies to glutamic acid decarboxylase manifested an insulin‐deficient phenotype, which is characteristic of classic type 1 diabetes mellitus[22](#jdi12957-bib-0022){ref-type="ref"}, whereas patients who are positive for only autoantibodies to islet antigen 2 do not differ from patients with type 2 diabetes mellitus in terms of clinical features[24](#jdi12957-bib-0024){ref-type="ref"}. Although the present findings together with the results of other studies[7](#jdi12957-bib-0007){ref-type="ref"} support the link between GV and DR in type 2 diabetes mellitus, most previous studies in type 1 diabetes mellitus failed to observe a significant association of short‐term GV with DR[13](#jdi12957-bib-0013){ref-type="ref"}, [14](#jdi12957-bib-0014){ref-type="ref"}, [15](#jdi12957-bib-0015){ref-type="ref"}, [18](#jdi12957-bib-0018){ref-type="ref"}. This phenomenon might partially account for the null association between GV and DR in LADA. Notably, it would be interesting to determine the association of GV with DR in different subgroups of LADA in the future.

A few limitations of the present study should be recognized. First, the sample size of patients with LADA was relatively small compared with that of type 2 diabetes mellitus, potentially limiting the statistical power in this group of individuals. Second, the cross‐sectional nature of this study precluded the possibility to examine the cause--effect relationship between GV and the development of DR. Third, the participants of the present study were recruited from the inpatients of our hospital, who presumably had worse metabolic control than outpatients. Therefore, the present findings might not be generalized to patients under a primary care setting.

In conclusion, the present study provides evidence that intraday GV, as assessed by CGM, is associated with the presence of DR in type 2 diabetes mellitus patients, but not in LADA patients, suggesting that GV should be minimized to decrease the risk of DR in type 2 diabetes mellitus, whereas achieving an optimal HbA~1c~ without increasing the risk of hypoglycemia might be the primary goal in the treatment of LADA. Future well‐designed studies with larger sample sizes are warranted to confirm the effect of GV on DR in clinically distinct subgroups of LADA.
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